IRF4 and plasma cell myeloma: The fact that two of the identified RIDD targets, IRF4 and IKZF1, are targeted by IMiDs, made us hypothesize that the combination of these drugs with ER-stress inducers (that also lowered IRF4 and IKZF1 levels) could exert a synergistic anti-myeloma effect.